- ISIN
- US3441741077
- CUSIP
- 344174107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 23, 2020
Highlights
- Market Cap
- $265.97M
- Enterprise Value
- $222.17M
- EPS (TTM)
- -$1.16
- Total Revenue (TTM)
- $28.22M
- Gross Profit (TTM)
- $3.25M
- EBITDA (TTM)
- -$72.40M
- Year Range
- $3.27 - $6.95
- Target Price
- $11.67
- ROA (TTM)
- -33.90%
- ROE (TTM)
- 98.58%
- Avg. Volume (1M)
- 345K
- Avg. Volume Value (1M)
- $1.91M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
FHTX Performance Chart
Foghorn Therapeutics Inc. (FHTX) is down 16.1% since the beginning of the year. At $5 per share, FHTX is trading 34.8% below its 52-week high of $7. Investors who bought $1,000 worth of FHTX shares 5 years ago would now be looking at an investment worth $500.
Loading charts...
Compare this symbol against anything
Returns By Period
Foghorn Therapeutics Inc. (FHTX) has returned -16.11% so far this year and -9.22% over the past 12 months.
Foghorn Therapeutics Inc.
- 1D
- -4.43%
- 1M
- -14.53%
- 6M
- -20.67%
- YTD
- -16.11%
- 1Y
- -9.22%
- 3Y*
- -21.35%
- 5Y*
- -12.96%
- 10Y*
- —
- ALL TIME*
- -22.01%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
FHTX Monthly Returns History
Based on dividend-adjusted daily data since Oct 23, 2020, FHTX's average daily return is +0.06%, while the average monthly return is +1.51%. At this rate, an investment would double in approximately 3.9 years.
Historically, 46% of months were positive and 54% were negative. The best month was Feb 2024 with a return of +143.1%, while the worst month was Jan 2024 at -50.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, FHTX closed higher 47% of trading days. The best single day was Feb 8, 2024 with a return of +55.5%, while the worst single day was Aug 23, 2022 at -25.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.74% | -0.53% | -15.85% | -0.63% | -9.89% | 14.02% | -7.17% | -16.11% | |||||
| 2025 | -11.23% | 15.75% | -24.74% | 15.07% | -2.86% | 15.20% | 11.70% | -3.62% | -3.36% | -9.82% | 7.71% | 13.68% | 14.41% |
| 2024 | -50.70% | 143.08% | -13.20% | -18.63% | 6.78% | -1.37% | 22.09% | 17.95% | 12.44% | -18.15% | 4.86% | -40.93% | -26.82% |
| 2023 | 34.80% | -33.37% | 8.20% | 5.16% | -3.53% | 11.92% | 30.11% | -17.36% | -33.95% | -33.00% | 26.87% | 51.76% | 1.10% |
| 2022 | -32.75% | -37.52% | 58.48% | -23.90% | 11.30% | 5.43% | 7.57% | -32.06% | -13.68% | 1.86% | -22.77% | -5.48% | -72.10% |
| 2021 | -18.60% | -0.24% | -19.93% | -16.69% | -5.19% | 2.50% | -15.00% | 43.11% | 7.32% | -8.90% | -8.83% | 97.67% | 12.83% |
Benchmark Metrics
Foghorn Therapeutics Inc. has an annualized alpha of -7.36%, beta of 1.54, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since October 23, 2020.
- This stock participated in 247.10% of S&P 500 Index downside but only 210.39% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.36%
- Beta
- 1.54
- R²
- 0.08
- Upside Capture
- 210.39%
- Downside Capture
- 247.10%
Return for Risk
Risk / Return Rank
FHTX ranks 36 for risk / return — above 36% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Foghorn Therapeutics Inc. (FHTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FHTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.60 | ||
| Sortino ratioReturn per unit of downside risk | -1.71 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.25 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.30 | 2.00 | -2.30 |
| Martin ratioReturn relative to average drawdown | -0.58 | 8.49 | -9.07 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Foghorn Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Foghorn Therapeutics Inc. was 89.10%, occurring on Feb 5, 2024. The portfolio has not yet recovered.
The current Foghorn Therapeutics Inc. drawdown is 82.50%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-89.10%Feb 2024 | 3y 1mo | — | 5y 7moDec 2020 - now | — |
-20.42%Oct 2020 | 5d | 1mo | 1mo 5dOct 2020 - Nov 2020 | — |
-18.14%Dec 2020 | 2d | 5d | 7dNov 2020 - Dec 2020 | — |
-12.97%Dec 2020 | 1d | 3d | 3dDec 2020 - Dec 2020 | — |
-8.67%Dec 2020 | 1d | 1d | 2dDec 2020 - Dec 2020 | — |
Drawdown Indicators
| FHTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.10% | -56.78% | -32.32% |
Max Drawdown (1Y)Largest decline over 1 year | -46.11% | -9.10% | -37.01% |
Max Drawdown (3Y)Largest decline over 3 years | -71.43% | -18.90% | -52.53% |
Max Drawdown (5Y)Largest decline over 5 years | -87.67% | -25.43% | -62.24% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -82.50% | -1.58% | -80.92% |
Average DrawdownAverage peak-to-trough decline | -66.62% | -10.70% | -55.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.62% | 2.14% | +21.48% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Foghorn Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Foghorn Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for FHTX relative to other companies in the Biotechnology industry. Currently, FHTX has a P/S ratio of 10.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with FHTX
Add Foghorn Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with FHTX